Kathleen Allor
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $12,008 of the $15,226 with a category attached, or 78.9%. It is spread thinly across 60 manufacturers, the largest accounting for just 20.1% — the pattern of someone who eats at a lot of different presentations. Among medical clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 718 payments — averaging $21.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$3K
- Johnson & Johnson$1K
- Merck$681
- AstraZeneca$680
- Incyte Corporation$629
- Genentech USA, Inc.$629
- plus $8K from 54 others
What the payments were for
- Food & beverage$12,00879%
- Education$1,1898%
- Other$2,03013%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$15,226 in reported general payments places this provider in the 95th percentile of 755 medical providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 34 | $503,844 |
| PomalystPomalidomide | 17 | $380,197 |
| ImbruvicaIbrutinib | 33 | $361,918 |
| IbrancePalbociclib | 21 | $324,954 |
| CalquenceAcalabrutinib Maleate | 22 | $300,723 |
| KisqaliRibociclib Succinate | 17 | $287,270 |
| Lenalidomide | 23 | $271,673 |
| PromactaEltrombopag Olamine | 11 | $75,599 |
| EliquisApixaban | 42 | $28,270 |
| Anastrozole | 192 | $9,441 |
| Exemestane | 12 | $2,354 |
| Tamoxifen Citrate | 58 | $1,624 |
| Letrozole | 35 | $1,133 |
| Prochlorperazine Maleate | 46 | $1,116 |
| Dexamethasone | 34 | $767 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $168 | $503,84434 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $373 | $380,19717 claims |
| NovartisKisqali, Promacta | $3,057 | $362,86928 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $238 | $361,91833 claims |
| PfizerIbrance, Eliquis | $127 | $353,22463 claims |
| AstraZenecaCalquence | $680 | $300,72322 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 755 medical providers in Michigan.
Other medical in Troy
- Beth BeleskyTroy$8K
- Caleb YoungbloodBerkley$215K
- Steven StoneKalamazoo$200K
- Meredith KentGrand Rapids$192K
- Amber ShullNorton Shores$154K
- Jason EvansWaterford$104K
- James ToreySaint Clair Shores$56K
- David WilkinsMuskegon$41K
- Mark RosenBerkley$32K
- Robert DemeesterRoyal Oak$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.